Smart CAR RNA Control Devices for Toxicity Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T-cell therapies for treating malignancies face challenges with toxicity due to the persistence of non-responsive CAR T-cell clones and the difficulty in controlling acute toxicity, as existing kill switches and transient CAR expression methods do not effectively safeguard against long-term surveillance benefits.
Innovation Solution
Development of Smart-CAR, DE-CAR, and Side-CAR constructs that comprise nucleic acids encoding chimeric antigen receptors combined with RNA control devices, which include sensor, linker, and actuator elements to regulate CAR polypeptide expression in response to small molecules or stimuli, allowing for customizable and controlled CAR activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If kill switch technology is used to control CAR T-cells, then safety against toxicity is improved, but reliability of toxicitiesafeguard is worsened due to non-responsive clones and retroviral copying errors
Solution Approach 1:
The CAR construct is divided into two separate expression cassettes: one expressing the CAR polypeptide and another expressing a destabilizing element. This segmentation allows independent control of CAR expression and destabilizing element activity, enabling more reliable toxicity control since the destabilizing element can be activated to eliminate CAR-expressing cells regardless of CAR responsiveness status.
Solution Approach 2:
An RNA control device acts as an intermediary between the destabilizing element and CAR expression control. The RNA control device responds to small molecule ligands and regulates destabilizing element expression, providing a reliable intermediary control mechanism that bypasses potential failures in direct CAR kill switch systems.
2Object-affected harmful factors
If transient CAR expression is used, then acute toxicity control is improved, but loss of surveillance benefit is worsened
Solution Approach 1:
The system uses dynamic control of CAR expression through the RNA control device that responds to small molecule ligands. CAR expression can be transiently reduced or eliminated to control acute toxicity, then restored when needed for surveillance, providing temporal dynamics that resolve the contradiction between acute toxicity control and long-term surveillance benefit.
Solution Approach 2:
The system changes the expression parameter of CAR over time through controlled destabilizing element activity. By modulating the stability parameter of CAR protein via the RNA control device and destabilizing element, the system can transiently reduce CAR levels to control toxicity, then restore them for surveillance, maintaining both acute safety and long-term benefit.
3Duration of action of stationary object
If stable transgene insertion is used, then long-term surveillance benefit is improved, but reliability of kill switch is worsened due to selection pressures and copying errors
Solution Approach 1:
By segmenting the CAR system into separate CAR expression and destabilizing element expression cassettes, the invention creates a more reliable kill switch mechanism. The destabilizing element can be independently activated to eliminate CAR-expressing cells, providing a backup reliability mechanism that overcomes selection pressures and copying errors affecting single-construct kill switches.
Solution Approach 2:
The RNA control device provides feedback control by responding to small molecule ligands and regulating destabilizing element expression. This feedback mechanism enhances kill switch reliability by providing continuous control capability that can respond to and correct potential failures in the stable transgene system.
Data Source
AI summary
RNA Control Devices and/or destabilizing elements (DE) can regulate the expression of Chimeric Antigen Receptors (CARs) in eukaryotic cells. More specifically, DEs, RNA Control Devices, and/or side-CARs can be used with small molecule ligands to regulate the expression of Chimeric Antigen Receptors. These DE-CARs, Smart CARs (Smart=small molecule actuatable RNA trigger), Smart-DE-CARs, and/or Side-CARs can be used in the treatment of disease.